CareFusion 213, LLC Initiates Class I Recall of ChloraPrep Applicators Due to Non-Sterility
CareFusion 213, LLC has initiated a Class I recall of 205,440 BD ChloraPrep Clear 1mL Applicators due to Aspergillus penicillioides contamination from package lidding breach. This poses a severe patient safety risk, demanding immediate action from procurement and supply chain leaders to secure alternative sterile preoperative skin preparations and reassess supplier quality protocols for critical medical supplies.
FDA Class I Recall: Aspergillus Contamination in CareFusion ChloraPrep Applicators
CareFusion 213, LLC, a subsidiary of Becton, Dickinson and Co., has initiated a Class I recall of 205,440 units of its BD ChloraPrep Clear 1mL Applicators. This critical action, designated recall number D-0259-2025, was voluntarily initiated by the firm on February 14, 2025, and subsequently classified by the FDA on March 7, 2025, due to a severe non-sterility issue. The product, a sterile solution containing 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), is intended for patient preoperative skin preparation. The root cause identified for this recall is contamination by *Aspergillus penicillioides*, a mold, stemming from a breach in the package lidding. This directly compromises the sterility of a product designed for use on patients prior to surgical procedures, posing a significant risk of infection. For procurement directors, this means an immediate and critical assessment of existing inventory of Lot #: 3200240, with an expiration date of June 30, 2026. Regulatory affairs heads must ensure swift compliance with recall procedures and reporting requirements, understanding that a Class I classification signifies a high probability of serious adverse health consequences or death. Supply chain VPs face the urgent task of quarantining affected stock and securing alternative sterile skin preparation solutions to prevent disruptions in surgical schedules and maintain patient safety standards.
Manufacturing Facility and Product Profile Under Scrutiny
The affected BD ChloraPrep Clear 1mL Applicators (NDC 54365-400-31, REF 930480), marketed under the brand name CHLORAPREP ONE-STEP, are manufactured by CareFusion 213, LLC at its facility located in El Paso, TX, United States. This facility is a key production site for topical antiseptic solutions critical to healthcare settings. The product, an over-the-counter (OTC) human drug, is crucial for infection control protocols in hospitals and clinics nationwide and in Canada, where it has been distributed. For business development executives, this incident highlights the vulnerability of single-source or concentrated manufacturing locations for essential medical supplies. The El Paso facility's output of this specific chlorhexidine gluconate and isopropyl alcohol formulation is now under intense scrutiny. Procurement teams must evaluate not only the immediate recall but also the long-term reliability of this manufacturing site, considering potential future regulatory actions or production delays as CareFusion addresses the identified packaging integrity issues. Understanding the geographical concentration of such critical product manufacturing is vital for strategic sourcing and risk diversification planning.
Supply Chain Exposure and Immediate Market Impact of Class I Recall
The Class I recall of 205,440 BD ChloraPrep Clear 1mL Applicators has created an immediate and severe disruption across the healthcare supply chain in both the United States and Canada. As a preoperative skin preparation, this product is indispensable for maintaining aseptic conditions during surgical procedures. The contamination with *Aspergillus penicillioides* means that any use of the recalled Lot #: 3200240 (Exp 6/30/2026) could introduce a fungal infection, leading to potentially life-threatening complications for patients. Procurement directors must act decisively to identify and quarantine all affected units within their systems, initiating returns to CareFusion 213, LLC. The immediate business impact is a critical shortage of a widely used antiseptic, necessitating rapid sourcing of alternative products. Supply chain VPs must assess their entire inventory of similar products, even from different lots or manufacturers, to ensure robust quality control and prevent cascading shortages. Regulatory affairs heads are tasked with navigating the complex reporting requirements associated with a Class I recall, which demands transparency and swift communication with healthcare providers and regulatory bodies to mitigate patient risk and maintain compliance.
Identifying Alternative Sterile Antiseptic Suppliers Amidst Shortages
In the wake of CareFusion 213, LLC's Class I recall, procurement directors face an urgent imperative to identify and qualify alternative suppliers for sterile preoperative skin preparations containing chlorhexidine gluconate and isopropyl alcohol. While specific alternative suppliers are not detailed in our current intelligence, the market for such critical antiseptics includes several established pharmaceutical and medical device manufacturers. Companies like 3M (with products such as Cavilon and DuraPrep), PDI Healthcare (with Sani-Cloth CHG), and Medline (with various CHG prep solutions) typically offer similar formulations. The qualification process for new suppliers, especially for sterile products, is rigorous and time-consuming, involving comprehensive quality audits, regulatory documentation review, and often, stability testing. Supply chain VPs must prioritize suppliers with proven track records of cGMP compliance and robust quality management systems. Geographic diversity in sourcing is also paramount to build resilience against localized disruptions. Business development executives should monitor this shift in demand, as it presents opportunities for competitors to gain market share, while procurement teams must navigate potential price fluctuations and extended lead times during this period of heightened demand for alternative sterile antiseptic solutions.
Regulatory Implications and Remediation Pathways for CareFusion
The Class I recall of BD ChloraPrep Clear 1mL Applicators places significant regulatory pressure on CareFusion 213, LLC and its parent company, Becton, Dickinson and Co. While the recall was voluntarily initiated by the firm, the FDA's Class I classification underscores the severity of the non-sterility issue and the potential for serious patient harm. Regulatory affairs heads should anticipate heightened scrutiny from the FDA on CareFusion's manufacturing processes at its El Paso, TX facility, particularly concerning packaging integrity and aseptic processing controls. CareFusion is now obligated to conduct a thorough root cause analysis of the package lidding breach that led to *Aspergillus penicillioides* contamination. This will necessitate the implementation of comprehensive Corrective and Preventive Actions (CAPA) to prevent recurrence. For procurement and supply chain leaders, this means potential long-term impacts on product availability from this facility as remediation efforts are undertaken and verified by regulatory bodies. Future FDA inspections will critically assess the effectiveness of these CAPA measures. Companies relying on CareFusion for other sterile products should proactively engage with their supplier relations teams to understand the broader implications for quality assurance across their portfolio.
Broader Industry Context and Risk Mitigation Strategies for Sterile Products
This Class I recall by CareFusion 213, LLC serves as a critical reminder for the entire chemical and life sciences industry regarding the paramount importance of robust quality control and supply chain resilience, especially for sterile products. While the specific event involves *Aspergillus penicillioides* contamination due to a package lidding breach, it echoes broader concerns about manufacturing quality and sterility assurance that have impacted other firms, such as Essential Wellness Pharma's recent Class II recall for progesterone injection sterility failures in 2026. For senior decision-makers, this incident necessitates a proactive review of internal quality management systems, particularly those governing packaging materials, sealing processes, and environmental monitoring in aseptic manufacturing environments. Procurement directors should mandate comprehensive supplier audits that include detailed assessments of packaging lines and sterility assurance protocols. Supply chain VPs must stress-test their contingency plans for critical medical supplies, ensuring that diversified sourcing strategies are in place to mitigate the impact of similar high-severity recalls. Business development executives should recognize the increasing regulatory scrutiny and consumer demand for impeccable product safety, integrating these factors into market strategies and product development.